MarketBeat
13 May 2026, 03:07 UTC · 21w ago
Verdict
Headline leans bullish. We score ASTH +0.90 across six claims.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+0.90strongly bullish
What the story claims
6 claims · scored −1 bearish … +1 bullish
Astrana's Q1 medical cost trend improvement at Prospect was already better than the 50-basis-point target, and Q1 trends came in better than assumptions across Medicare Advantage, commercial, and Medicaid.
So whatBeating medical cost trend assumptions directly reduces medical losses and boosts margins, which is a primary driver for healthcare stock valuations.
More positive than 99% of claims this week
Astrana is tracking toward the high end of its $12 million to $15 million synergy range for the Prospect acquisition and has begun realizing revenue synergies by combining payer contracts.
Continue reading
5 related stories
More positive than 95% of ticker scores this week
Scored by the NIS engine · methodology.
Search tags
More positive than 98% of claims this week
Astrana views its effective Medicare Advantage rate impact at 4% to 6%, well above the 2.5% net average, because disallowed diagnosis practices do not affect its model, and projected CMS risk adjustment changes represent a 1.5% headwind versus the 2.5% industry average.
So whatA favorable regulatory impact relative to peers provides a structural margin advantage in a heavily regulated market, de-risking future earnings.
More positive than 98% of claims this week
Q1 free cash flow was up roughly three times year over year and revenue growth was well over 40% to 50%, trending ahead of expectations.
More positive than 98% of claims this week
Which stocks this story touches
More positive than 95% of ticker scores this week
The company reported stronger-than-expected Q1 results, successful integration of Prospect, and growth exceeding 40-50%.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
3d ago
−4.4%
Price is moving against the score
$37.29 vs $39.01 close before publication (May 12) · not market-adjusted
ASTH chart →
